

Sub 52 20. The anti-human antigen receptor according to any one of claims 18, 19, 65, 66 or 67, said anti-human antigen receptor being specific for a human tumor antigen.

21. The anti-human antigen receptor according to any one of claims 18, 19, 65, 66 or 67, said anti-human antigen receptor being specific for the native human 17-1A antigen.

Sub 2 22. The anti-human antigen receptor according to any one of claims 18, 19, 65, 66 or 67, wherein said VH comprises at least one CDR of the amino acid sequence corresponding to nucleotides 1 to 381 of Seq. ID NO: 143 and said VL chain comprises at least one CDR of the amino acid sequence corresponding to nucleotides 1 to 321 of Seq. ID No: 141.

Sub 1 29. The anti-human antigen receptor of claim 28 said anti-human antigen receptor being low or not immunogenic in humans.

Sub 4 31. The anti-human antigen receptor of claim 28 recognizing an epitope of the extracellular domain of the 17-1A antigen, said epitope comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 29, 32, 34, 35, 80, 81, 98, 100.

I 4 32. The anti-human antigen receptor of claim 28, wherein the VH chain comprises at least one CDR of one of the following two sequences shown in Fig. 7 (corresponding to nucleotides 1 to 381) and Fig. 8 (corresponding to nucleotides 1 to 339) and/or the VL chain comprises at least one CDR of the following two sequences shown in Fig. 6 (corresponding to nucleotides 1 to 321) and Fig. 9 (corresponding to nucleotides 1 to 321).

I 5 34. The anti-human antigen receptor according to claim 18, 65, 66 or 67, said anti-human antigen receptor comprising a VH chain or at least one CDR. — F

I 6 36. The anti-human antigen receptor according to claim 18, 65, 66 or 67, said receptor comprising a VL chain or at least one CDR.

38
I7
38. A pharmaceutical composition comprising an anti-human antigen receptor according to claim 18, 65, 66 or 67, comprising a VH chain and a VL chain and a pharmaceutically acceptable carrier.

I8
43. A pharmaceutical composition comprising an anti-human antigen receptor according to claim 18, 65, 66 or 67, comprising at least one CDR and a pharmaceutically acceptable carrier.

3. Please add a new claims 65-75 to read:

38
I5
65. The anti-human antigen receptor according to claim 18, obtained by a method further comprising the steps of obtaining, after selection, the suitable human VH and VL chains or the corresponding nucleic acids, and fusing said chains or the corresponding nucleic acids to: (a) the same or other VH or VL chains or the corresponding nucleic acids, (b) immunoglobulin constant regions of heavy (CH) or light chains (CL) or parts thereof or the corresponding nucleic acids, or (c) non-immunoglobulin chains or the corresponding nucleic acids, respectively.

38
I5
66. The anti-human antigen receptor according to claim 65, wherein said constant region chains are derived from human IgG1 or IgG3.

I9
38
I6
67. The anti-human antigen receptor according to claim 18, obtained by a method further comprising the steps of obtaining, after selection, the human VH and VL chains and physically linking said chains to non-proteinous pharmaceuticals and/or other biologically active molecules.

68. The anti-human antigen receptor of claim 31 in which said epitope comprises the amino acid sequence of SEQ ID NO:29.

69. The anti-human antigen receptor of claim 31 in which said epitope comprises the amino acid sequence of SEQ ID NO:32.

70. The anti-human antigen receptor of claim 31 in which said epitope comprises the amino acid sequence of SEQ ID NO:34.

71. The anti-human antigen receptor of claim 31 in which said epitope comprises the amino acid sequence of SEQ ID NO:35.

72. The anti-human antigen receptor of claim 31 in which said epitope comprises the amino acid sequence of SEQ ID NO:80.

73. The anti-human antigen receptor of claim 31 in which said epitope comprises the amino acid sequence of SEQ ID NO:81.

I9
Cont 74. The anti-human antigen receptor of claim 31 in which said epitope comprises the amino acid sequence of SEQ ID NO:98.

75. The anti-human antigen receptor of claim 31 in which said epitope comprises the amino acid sequence of SEQ ID NO:100.